Entries by raincastle

Revere Pharmaceuticals Enters Exclusive Option and License Agreement with Fosun USA to Develop and Commercialize Products Targeting Rac1 and Cdc42 in China

Boston, Mass. — Revere Pharmaceuticals, an emerging biopharmaceutical company developing small molecule drugs targeting the Ras-homologous (Rho) family GTPases, announced the completion of an exclusive option and license agreement with Fosun USA to develop and commercialize products targeting Rac1 and Cdc42 in China.  Under the terms of the agreement, the license grants Fosun rights to […]